Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.

Eli Lilly's stock has declined 8% recently after a 41% gain over 12 months. The pullback is attributed to profit-taking following a historic run. Despite concerns about product pricing and valuation multiples, the company's strong GLP-1 drug demand and growth prospects remain intact. Historical data shows Lilly has rebounded strongly from similar pullbacks, and Wall Street analysts remain overwhelmingly bullish with a consensus 16% upside target.